BASEL, August 20, 2026, 00:40 CEST
- Roche bearer shares finished up 1.53% at CHF372.40 on August 19.
- Morgan Stanley forecasts peak giredestrant sales at CHF9 billion, exceeding consensus by CHF2.4 billion.
- Sales for the first half were up 6% at constant exchange rates but declined 2% in Swiss francs.
Shares in Roche Holding Ltd (SWX:RO; SWX:ROP) climbed 1.53% to CHF372.40 on Wednesday. The bullish outlook for the stock is now more closely connected to a broad range of sales projections for its breast cancer drug giredestrant.
Morgan Stanley projects peak sales of giredestrant at CHF9 billion, while the wider market consensus stands at approximately CHF6.6 billion. The CHF2.4 billion difference accounts for 3.9% of Roche’s expected group revenue in 2025.
Swiss markets are not open. Roche shares rose after a robust two-week re-rating that began with its August 7 upgrade to Overweight. Investors are now confronted with a narrower margin for execution errors ahead of two upcoming U.S. regulatory decisions expected towards year-end.
Roche’s valuation is similar to that of leading European pharmaceutical firms. Novartis AG SWX:NOVN has a trailing multiple that is almost the same. AstraZeneca PLC LON:AZN shows quicker earnings growth, though with a reduced yield. Novo Nordisk A/S CPH:NOVO-B is priced at under half of Roche’s multiple.
| European pharma | Aug. 19 move | Trailing P/E | EPS growth, TTM | Dividend yield |
|---|---|---|---|---|
| Roche | up 1.53% | 24.30x | rising 30.49% | 2.94% |
| Novartis | up 1.24% | 24.18x | down 11.50% | 2.95% |
| AstraZeneca | up 2.07% | 24.18x | up 21.16% | 2.08% |
| Novo Nordisk | up 1.05% | 11.43x | up 5.13% | 3.95% |
Roche’s operating performance in the first half underpins its premium valuation. Sales climbed 6% at constant exchange rates, while core operating profit rose 10%. However, gains were largely offset in Swiss franc terms due to currency movements.
| First-half 2026 measure | Reported value | Change at CER | Change in CHF |
|---|---|---|---|
| Group revenue | CHF30.36bn | +6% | -2% |
| Pharmaceutical revenue | CHF23.63bn | +6% | -1% |
| Diagnostics revenue | CHF6.74bn | +3% | -3% |
| Core operating income | CHF11.86bn | +10% | -1% |
| Core diluted earnings per share | CHF10.85 | +9% | -2% |
Chief Executive Thomas Schinecker stated, “Our regulatory momentum accelerated significantly as the US FDA granted five Priority Reviews.” Roche maintained its forecast for sales growth in the mid-single digits and aims for a high-single-digit increase in core EPS. Roche
Giredestrant produces the most significant differentiation in projected valuations. Morgan Stanley anticipates first-year sales of CHF660 million and a peak of CHF9 billion. The bank’s peak estimate stands 36% higher than consensus. Its forecast for 2027 core EPS is CHF22.96, surpassing the previous consensus by 5.2%.
| Giredestrant measure | Morgan Stanley | Reference point | Gap |
|---|---|---|---|
| First-year sales | CHF0.66bn | — | Launch forecast |
| Peak sales | CHF9.0bn | CHF6.6bn consensus | +CHF2.4bn |
| Peak sales / 2025 group sales | 14.6% | 10.7% consensus | +3.9 points |
| 2027 core EPS | CHF22.96 | CHF21.83 consensus | +5.2% |
| Early-stage FDA decision | Nov. 30, 2026 | Priority Review | Binary event |
| Metastatic FDA decision | Dec. 18, 2026 | Expected decision | Binary event |
Analyst price targets highlight a similar split. The average among 18 analysts is CHF363.92, with Bernstein projecting a high of CHF434.50. These figures refer to Roche participation certificates, SWX:ROP, not the less frequently traded bearer shares.
| Analyst or consensus | Recommendation | Target | Update |
|---|---|---|---|
| 18-analyst consensus | Buy | CHF363.92 average | August 2026 snapshot |
| Bernstein | Outperform | CHF434.50 | July 27, 2026 |
| Morgan Stanley | Overweight | CHF410.00 | August 7, 2026 |
| UBS | Buy | CHF376.00 | July 23, 2026 |
| Goldman Sachs | Neutral | CHF365.00 | January 16, 2026 |
The franc continues to be a distinct drag on earnings. Constant exchange rates saw reported first-half sales drop by 2%. Any additional currency appreciation may erode pipeline growth for shareholders who report in francs.
Risks: In March, giredestrant failed to meet its combination endpoint in the first-line setting. Regulatory reviews in the United States may face postponements or denials. Weaker adoption could cause revenue to align more closely with the CHF6.6 billion consensus instead of the higher bull scenario.
In the coming week, investors will monitor currency fluctuations and any updates regarding the FDA’s schedule. Roche’s capital-markets day on September 28 is the next significant company event on the calendar. Prior to that, valuation discussions are expected to hinge largely on giredestrant assumptions.
Related articles: Pharmaceuticals
The bull case needs CHF9bn
RO close
Market value
Trailing P/E
Dividend yield
Giredestrant peak-sales gap · CHF bn
First-half currency split
| Measure | Value | CER | CHF |
|---|---|---|---|
| Group sales | 30.36bn | +6% | −2% |
| Pharma sales | 23.63bn | +6% | −1% |
| Diagnostics | 6.74bn | +3% | −3% |
| Core operating profit | 11.86bn | +10% | −1% |
| Core EPS | CHF10.85 | +9% | −2% |
European pharma comparison
| Company | P/E | EPS growth | Yield |
|---|---|---|---|
| Roche | 24.30× | +30.49% | 2.94% |
| Novartis | 24.18× | −11.50% | 2.95% |
| AstraZeneca | 24.18× | +21.16% | 2.08% |
| Novo Nordisk | 11.43× | +5.13% | 3.95% |
ROP analyst targets
| View | Target | Rating |
|---|---|---|
| 18-analyst average | CHF363.92 | Buy |
| Bernstein | CHF434.50 | Outperform |
| Morgan Stanley | CHF410.00 | Overweight |
| UBS | CHF376.00 | Buy |
| Goldman Sachs | CHF365.00 | Neutral |
